景顺股票讨论区

胡珀对央行的模糊表述持怀疑态度，认为其在控制通胀方面可能行动不迅，可能给市场带来正面意外。他正在关注更多发达国家的抗通胀数据，特别关注美国经济放缓的迹象，并强调全球范围内，股票、固定收益及另类投资布局的重要性。

$景顺(IVZ.US)$$Myovant Sciences(MYOV.US)$ 
3 reasons to consider MYOV
1) great fundamentals - great leaps in price to sales ratio (value) and also enterprise value to EBITA (growth) Q to Q
a) 2 approved life saving/changing blockbusters and more pending. Not going into technical but manydoctors and client attested to the benefits and the increasing scripts speaks of itself
b) strong financials - huge cash runway of $6b+ cash for a $1.4b market capital company with incoming streams of income from tiered payments and commercialising sales of 2 great products
c) Experienced Pfizer commercialising the above drugs.. acknowledging the value with 4.2b tiered payment.. Pfizer taking this on also speaks volume andthe confidence in the 4.2b price for 50%
2) Buyout Target for Sumi who is facing a patent cliff and can fully own last of the “vant” company or secondary contender PFizer who is flooded with cash and looking to buy. Lots of M&A happening in this space.
3)Fantastic Value and looking at a reversal trend. Cyclical move into biomed.. great oppty and timing for the buyout before price become higher…and short squeeze due to manupulation of the bullies in a Low float enviroment… through observation of the capital flow trends and also price movements

Invesco rose more than 7.67 percent to $26.80 in premarket trading on Friday.
On the news, according to people familiar with the matter, Invesco is in merger talks with State Street asset management.
It is unclear whether the merger talks will succeed, but it could be one of the industry's largest mergers in recent years, given that State Street's asset management unit manages nearly $4 trillion in assets, people familiar with the matter said.
$景顺(IVZ.US)$

$景顺(IVZ.US)$
Wow! that came out of no where. Get in on this blue chip, offices in 20 countries and excellent financials.